#USA #Chicago #Barrett's Esophagus #Castle Biosciences #TissueCypher

New Insights into Barrett's Esophagus Management with TissueCypher® Testing

At the Digestive Disease Week 2026 (DDW 2026) held in Chicago, Castle Biosciences, Inc. unveiled exciting new research regarding its TissueCypher test. This innovative molecular test is designed to improve risk stratification and management for patients diagnosed with Barrett's Esophagus (BE).

Researchers from the esteemed Mayo Clinic conducted studies showcasing how the TissueCypher test refines risk assessment, offering actionable insights that enhance patient management strategies. The implications of these findings could revolutionize treatment paths for many patients suffering from BE and help physicians deliver personalized healthcare that is more aligned with individual risk profiles.

Key Findings from the DDW Presentations

The research presented at DDW is centered around two pivotal posters that demonstrate how the TissueCypher test’s molecular approach improves clinical decisions over traditional histopathologic assessments. One poster highlights findings from a study that indicates substantial changes in surveillance intervals for more than half of the patients tested. This marked increase in tailored management illustrates the substantial role of molecular risk stratification in clinical practice.

Dr. Cadman L. Leggett, a gastroenterologist at Mayo Clinic and senior author of the studies, emphasized the findings, stating, "The evidence presented reflects that traditional risk assessment may not fully encapsulate a patient's true risk of progression. By utilizing TissueCypher's molecular risk stratification, we can derive clinically actionable insights that lead to more accurate patient management decisions."

Study Highlights

1. Impact on Surveillance Intervals: In a cohort of patients assessed using the TissueCypher test, 55% of those showed modified surveillance intervals following the testing. Physicians recommended shorter intervals for 93% of patients assessed as intermediate to high risk, reflecting an escalation of care informed by test results. Notably, even among patients classified as low-risk traditionally, the test identified 92% of those as intermediate/high risk, advocating for a reshaped approach to surveillance strategies.

2. Comparative Risk Stratification: Another major point of research presented was the comparison between the TissueCypher test outcomes and traditional clinical risk models, such as the Progression in Barrett's Esophagus (PIB) model. The TissueCypher testing identified significantly more patients as low risk (84% vs. 38%) and exhibited minimal agreement with PIB findings, suggesting that PIB may overlook higher risk patients who could greatly benefit from targeted interventions.

Transforming Clinical Practice

The implications of these findings extend beyond just academic interest; they represent a significant leap towards personalized medicine. The use of TissueCypher allows healthcare providers to make more informed decisions on patient surveillance and treatment strategies, ultimately leading to enhanced patient outcomes. By identifying patients who may need more aggressive surveillance or intervention, healthcare professionals can enhance the quality of care provided to those at risk of esophageal cancer progression.

The TissueCypher test employs a unique AI-driven spatialomics approach to evaluate standard endoscopic pinch biopsies, granting rapid and reliable analysis without additional invasive procedures. This integration into routine practice makes the test not only beneficial but practical in the everyday clinical setting.

Conclusion

As Castle Biosciences continues to innovate in the field of molecular diagnostics, the results shared at DDW 2026 underline the company's commitment to improving health outcomes specifically for patients with Barrett's Esophagus. With rigorous validation through extensive research and a patient-centered approach, TissueCypher positions itself as a formidable tool in gastroenterology, capable of driving better and more personalized patient management practices.

To learn more about the research and Castle Biosciences' innovative tests, you can visit their booth at DDW 2026 or explore available resources online.

By prioritizing patient individuality through advanced molecular diagnostics, the future of Barrett's Esophagus management looks exceedingly promising.